February 2019

Dear

Re: Important Information About Creon (Pancreatin) 40,000

As you have been prescribed Creon, we would like to inform you that Mylan the marketing authorisation holder for Creon, has decided to voluntarily discontinue the manufacture and distribution of Creon 40,000 from June 2019. It’s important to note that this decision is not associated with any safety or efficacy findings.

Compared to all other doses, producing Creon 40,000 requires a different concentration of active enzymes which have been decreasing over the last few years and because of this Creon 40,000 has experienced frequent supply constraints.

It is important to note that, Creon Micro, Creon 10,000 and Creon 25,000 will still be available in the UK with increased volumes to compensate for the discontinuation of Creon 40,000.

Creon capsules are interchangeable, therefore we advise that you speak with your healthcare professional regarding transferring to a different strength capsule to achieve the required dose. You should not be concerned about the efficacy when moving from one strength capsule to a different strength capsule.

Mylan will have a limited quantity of Creon 40,000 available up to June 2019.

If you have any questions, please contact Mylan Medical Information: info.uk@mylan.co.uk

If you have pancreatic cancer and would like further support regarding this discontinuation, please contact Pancreatic Cancer UK either by freephone: 0808 801 0707 or by email: nurse@pancreaticcancer.org.uk
For more information, visit pancreaticcancer.org.uk/getsupport

Yours sincerely,

Dr Ken Tam
Senior Medical Advisor

---

If you get any side effects, talk to your doctor, pharmacist, dietitian or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the yellow card scheme at www.mhra.gov.uk/yellowcard.

By reporting side effects, you can help provide more information on the safety of these medicines.